Other languages Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Real-time Estimate Cboe BZX Other stock markets 09:53:55 2024-04-29 am EDT			5-day change	1st Jan Change
14.72 ^USD	-0.03%		+0.20%	+10.07%

Mar. 27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT
Mar. 07	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	Nov. 16
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Insider Buy: Merrimack Pharmaceuticals	23-08-09
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Insider Buy: Merrimack Pharmaceuticals	23-03-22
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09
Insider Buy: Merrimack Pharmaceuticals	23-02-01
Insider Buy: Merrimack Pharmaceuticals	23-01-31
Insider Buy: Merrimack Pharmaceuticals	23-01-17
Insider Buy: Merrimack Pharmaceuticals	23-01-03
Merrimack Pharmaceuticals Shares Soar as Partner Ipsen Says Pancreatic Cancer Drug Study Meets Main Endpoint	22-11-09
ETF Preview: ETFs, Stock Futures Down Pre-Bell After Mortgage Applications Report	22-11-09
Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	22-11-09
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04
Merrimack Says Ipsen's Phase 3 Trial of Onivyde to Treat Lung Cancer Didn't Meet Primary Endpoint; Merrimack Shares Drop	22-08-03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Other languages

Filters